PITTSBURGH, March 4, 2025 /PRNewswire/ -- The PNC Financial Services Group, Inc. (NYSE: PNC) expects to issue financial results for the first quarter of 2025 at approximately 6:30 a.m. (ET ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long endeavor reached fruition in the form of a new treatment, CASGEVY ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

CRISPR Therapeutics did not record any collaboration expense for the fourth quarter of 2024, as it had reached the cost deferral limit for the Casgevy program in the previous quarter. As of Dec ...

I’m bullish on this Swiss gene-editing company, noting its strong financial position, first-to-market advantage with CASGEVY, and pipeline strength. Wall St. analysts are also impressed by the ...

Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs.

Morgan Stanley analyst Betsy Graseck maintained a Sell rating on PNC Financial (PNC – Research Report) today and set a price target of $209.00. The company’s shares closed yesterday at $194.21.

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes.

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...